Prolia 60 mg pre-filled syringe (denosumab)

Prolia is a prescription medication used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture. The active ingredient, denosumab, is a monoclonal antibody that inhibits the maturation of osteoclasts, the cells that break down bone. It is typically administered as a subcutaneous injection once every six months.

Originally developed by the American biotechnology company Amgen, Prolia has become one of the most widely recognized treatments in bone health. Manufacturing occurs at high-tech biotechnology facilities, primarily in Rhode Island (USA) and Puerto Rico, as well as sites across Europe to satisfy global demand.

Amgen remains the ultimate owner and developer of the product, maintaining its headquarters in Thousand Oaks, California. The brand is managed globally through Various Amgen subsidiaries depending on the region, such as Amgen Europe for the EU market.